Importantly, both the ZUMA-7 and TRANSFORM trials evaluated CD19 CAR T-cell therapy as second-line treatment for R/R large B-cell lymphomas, and the authors compared this to standard care treatment (two or three cycles of investigator-selected salvage chemo-immunotherapy followed by HDT/ASCR). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.